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Three hundred seven cases of patients who underwent operation for 
thymoma (196 of whom had myasthenia gravis) were analyzed to assess the 
prognostic values of Masaoka clinical staging, completeness of resection, 
histologic classification, history of myasthenia gravis, and postoperative 
radiotherapy. According to the Masaoka staging system, 135 thymomas 
were stage I, 70 were stage II, 83 were stage III, and 19 were stage IV. 
According to the Verley and Hollmann histologic lassification system, 67 
thymomas were type 1, 77 were type 2, 139 were type 3, and 24 were type 4. 
Two hundred sixty patients underwent complete resection, 30 underwent 
incomplete resection, and 17 underwent biopsy. Postoperative radiotherapy 
was performed mainly in cases of invasive or metastatic thymoma. Mean 
follow-up was 8 years; eight patients were unavailable for follow-up. The 
overall 10- and 15-year survivals were 67% and 57%, respectively. In 
univariate analysis, three prognostic factors were established: complete- 
ness of resection, Masaoka clinical staging, and histologic classification. 
Furthermore, among patients with stage II I  thymomas, survival was 
significantly higher for patients with complete resection than for patients 
with incomplete resection (p < 0.001). Completeness of resection should 
therefore be taken into account in clinical-pathologic staging. We did not 
find any significant difference with respect o disease-free survival between 
patients who had postoperative radiotherapy and those who did not. In 
multivariate analysis, the sole significant prognostic factor was complete- 
ness of resection. On the basis of these findings, a new clinical-pathologic 
staging system is proposed. (J Thorac Cardiovasc Surg 1996;112:376-84) 
T he prognostic factors for thymoma re difficult to establish and remain controversial. 1-7 There are 
various reasons for this; these tumors are uncom- 
mon, they are clinically and anatomically polymor- 
phic, they grow slowly, several histological classifi- 
cations have been used, and the series published to 
date are all retrospective. The aim of this study was 
to evaluate the prognostic values of clinical-patho- 
logic staging, completeness of resection, histologic 
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classification, association with myasthenia gravis 
(MG), and use of postoperative radiotherapy. 
Patients and methods 
Patients. Thymoma h s been defined as a tumor origi- 
nating from the epithelial cells of the thymus. We retro- 
spectively studied data from 307 consecutive patients 
operated on between 1955 and 1993 in the department of
Thoracic and Vascular Surgery of the Marie Lannelongue 
Hospital. There were 180 female (59%) and 127 male 
patients. The mean age was 49 years, ages ranged from 6 
to 77 years. 
One hundred ninety-five patients (64%) had MG. Eigh- 
teen patients had another autoimmune disease (OAD), 
isolated (14) or associated with MG (four): thyroiditis 
(six), systemic lupus erythematous (four), pure red cell 
aplasia (four), hypogammaglobulemia (two), Sj6gren's 
disease (two), pemphigus vulgaris (one), or hemolytic 
anemia (one). Ninety-seven patients had no autoimmune 
disease (NAD). 
The autoimmune disease revealed the thymoma in 85% 
of patients with MG and 65% of patients with OAD 
patients. Systematic chest radiography and mediastinal 
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compression symptoms revealed thymoma in two-thirds 
and one-third of patients with NAD, respectively. 
Methods. We performed a retrospective study to deter- 
mine long-term outcome after thymoma resection. Thy- 
momas were classified according to the Masaoka clinical- 
pathologic staging SygStem8 and to the Verley histologic 
classification system. 
At the beginning of our experience, patients with 
laterally located thymomas were operated on through a 
lateral thoracotomy; those with centrally located thymo- 
mas were operated on through asternotomy oran antero- 
lateral thoracotomy, according to the practice of the 
surgeon. During the last 15 years, almost all thymomas 
were operated on through a sternotomy, and these pa- 
tients underwent associated systematic thymectomy. 
The prognostic factors studied were Masaoka stage, 
completeness of resection, histologic lassification, asso- 
ciation with MG, and use of postoperative radiotherapy. 
Statistical analysis. Percentage comparisons were 
made by the continuity-corrected X 2 test. Survival and 
disease-free survival were calculated by the actuarial 
method and compared by the log-rank test. 1° Multivariate 
analysis was performed by the Cox proportional hazard 
11 model by means of BMDP statistical software. Results 
were considered significant if the p value was less than 
0.05. 
Results 
Extent of thymoma and surgical procedure. All 
307 patients were operated on; sternotomy, antero- 
lateral thoracotomy, and posterolateral thoracot- 
omy were performed in 55%, 30%, and 15% of the 
cases, respectively. At the time of the surgical 
procedure, thymoma was noninvasive in 52% of 
cases. When invasive, the tumor involved pleura 
(78%), pericardium (45%), lung (30%), phrenic 
nerve (30%), or superior vena caval system (27%). 
In 19 patients, the thymoma was initially metastatic; 
all metastases were intrathoracic (pleuropulmonary 
or pericardial), and all metastatic thymomas were 
also invasive to neighboring tissues. 
Two hundred ninety patients (94.5%) underwent 
tumor resection and 17 (5.5%) underwent biopsy 
only. Thymoma resection was enlarged to the 
pleura, pericardium, or both in 139 cases; to the lung 
in 27 cases (22 wedge resections, four pneumonec- 
tomies, one lobectomy); to one phrenic nerve in 14 
cases; to the superior vena caval system in 20 cases 
(17 innominate vein resections, three superior vena 
caval resections with graft reconstructions). Eighty- 
six percent of the patients underwent associated 
thymectomy. Some patients operated on through a 
posterolateral pproach did not undergo thymec- 
tomy. In eight patients, asecond small thymoma was 
identified by systematic histologic analysis of the 
thymus. 
Clinical and histologic staging. According to 
Masaoka and coworkers, 8 thymomas are classified 
as follows: stage I, macroscopically completely en- 
capsulated, and microscopically no capsular inva- 
sion; stage IIa, macroscopic nvasion into surround- 
ing fatty tissue, or mediastinal pleural tissue; stage 
IIb, microscopic invasion into capsule; stage III, 
macroscopic nvasion into neighboring organ (peri- 
cardium, great vessels, or lung); stage IVa, pleural 
or pericardial dissemination; stage IVb, lymphoge- 
nous or hematogenous metastasis. 
One hundred thirty-five thymomas (44%) were 
stage I, 70 (23%) were stage II, 83 (27%) were stage 
III, and 19 (6%) were stage IV. In addition to this 
classification, we divided patients with stage I tu- 
mors into two subgroups; 26 of these patients had 
significant peritumoral adherences assessed by in- 
traoperative analysis of the surgeon, although the 
tumor was macroscopically encapsulated and did 
not have capsular invasion. These 26 cases were 
classified as stage Ib; those without peritumoral 
adherence were classified as stage Ia. Among the 
288 nonmetastatic thymomas, according to the sur- 
geon and pathologist's analysis, 248 (86%) under- 
went complete resection (all stage I or II, 50% of 
stage III) and 40 (14%) underwent incomplete 
resection (28) or biopsy (12). Among the 19 cases of 
metastatic thymoma, we performed 12 complete 
resections, two incomplete resections, and five biop- 
sies. The distribution of the patients according to 
Masaoka clinical staging was similar in the patients 
with MG and with NAD. 
Histologic classification was made according to 
the work of Verley and Hollmann 9 as four types: 
spindle and oval cell thymomas (type 1), lympho- 
cyte-rich thymomas (type 2), differentiated epitheli- 
al-rich thymomas (type 3), and undifferentiated p- 
ithelial-rich thymomas (type 4). Sixty-seven (22%) 
thymomas were type 1, 77 (25%) were type 2, 139 
(45%) were type 3, and 24 (8%) were type 4. The 
correlations between Masaoka clinical stage and 
histologic type are summarized in Table I. Histo- 
logic type 3 and 4 tumors were often invasive or 
metastatic. The mean age of the patients with type 1 
thymomas was significantly higher than that of pa- 
tients with other types (56 + 12 vs 47 + 13 years, 
p < 0.01). 
Operative morbidity and mortality. Two hun- 
dred eighty-one patients (91.5%) had uneventful 
postoperative courses. Five patients (1.6%) died of 
respiratory, cardiac, or embolic omplications. Post- 
operative mortality was not influenced by MG. 
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Table I. Masaoka clinical stage according to histologic lassification 
Type 1 (n = 67) Type 2 (n = 77) Type 3 (n = 139) Type 4 (n = 24) 
No. % No, % No. % No. % 
Stage I 52 78 48 62 35 25 0 0 
Stage II 7 10 17 22 45 32 1 4 
Stage III 7 10 11 14 44 32 21 88 
Stage IV 1 1 1 1 15 11 2 8 
Percentages do not necessarily add to 100% as a result of rounding. 
Table II. Cause of death according to Masaoka 
clinical stage 
Stage I Stage H Stage III Stage IV 
(n =135) (n =70) (n -83)  (n -19)  
Total deaths 29 10 39 14 
Postoperative deaths 3 1" 1 2* 
Tumor 1 2 20 9 
Autoimmune disease 7 3 12 1 
Miscellaneous disease 15 2 6 2 
Unknown 3 2 0 0 
*Two of these three patients died after another resection for recurrence. 
Twenty-one patients (6.9%) had complications ne- 
cessitating medical treatment: pulmonary infections 
(12), respiratory failure (eight), parietal infections 
(five), and pulmonary embolism (two). Fifty-eight 
percent of the 196 patients with MG required 
postoperative mechanical ventilation for longer than 
3 days. The 12 pulmonary infections and the eight 
respiratory failures occurred in patients with MG. 
Adjuvant herapy. Adjuvant herapy was not car- 
ried out according to a protocol in this retrospective 
study. Our policy was to perform postoperative 
radiotherapy in cases of invasive thymoma. Finally, 
postoperative radiotherapy was performed in 13% 
of cases of stage I tumors, 78% of stage II cases, and 
83% of stage III cases. Among the 19 metastatic 
cases of thymoma (stage IV), 90% of the patients 
had postoperative radiotherapy, chemotherapy, or
both. 
Long-term results. Follow-up data were obtained 
for 299 patients until either death or completion of 
the study (January 1994). Eight patients were un- 
available for follow-up. Mean follow-up was 8 years, 
and follow-up exceeded 10 years in one-third of the 
cases (median follow-up 5.5 years, range 1 to 28 
years). 
At completion of the study, 92 patients had died. 
Thirty-two (35%) died of progressive tumor, 23 
(25%) died of progressive autoimmune disease, 25 
(27%) died of miscellaneous diseases, and 7 (8%) of 
postoperative complications. The cause of death 
remained unknown in five patients (5%), all of 
whom underwent complete resection of a stage I or 
II spindle cell or lymphocyte-rich t ymoma. Table II 
shows the cause of death according to Masaoka 
clinical stage. 
The overall actuarial 10- and 15-year survivals 
were respectively 67% and 57%. The 10-year surviv- 
als were 70% for patients with MG, 74% for patients 
with OAD, and 62% for patients with NAD; there 
were no significant differences among these three 
groups of patients. Fig. 1 shows the actuarial survival 
curves according to Masaoka clinical stage. No 
significant difference was found between survival 
curves of patients with stage I and II tumors (p = 
0.70). On the other hand, survival was significantly 
longer for patients with stage II tumors than those 
with stage III tumors (log rank test p < 0.001). 
Similarly a borderline significant difference was 
found between survival curves of patients with stage 
IIa and IIb tumors (10-year survivals 100% and 
74%, respectively, p = 0.09). No significant differ- 
ence was found between survival curves of patients 
with stage III and stage IV tumors (p = 0.25). 
Regarding the completeness of thymoma resec- 
tion, the actuarial 10-year survival for patients with 
complete resection was significantly higher than 
those of patients with incomplete resection or bi- 
opsy (76% and 28%, respectively, log rank testp < 
0.0001; Fig. 2). Furthermore, survival was signifi- 
cantly higher among patients with stage III disease 
that was completely resected than among those with 
incomplete resection or biopsy; 10-year survivals 
were respectively 75% and 31%, respectively (log 
rank test p < 0.001, confidence intervals 57% to 
91% and 15% to 46%, respectively). Survival was 
also significantly longer for patients with completely 
resected stage III thymomas than for patients with 
completely resected stage IV thymomas. Ten-year 
survivals were 75% and 42%, respectively (p < 0.05, 
confidence intervals 57% to 91% and 12% to 72%, 
respectively). On the other hand, although survival 
was higher among patients with completely resected 
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Fig. 1. Actuarial survival according to Masaoka clinical stage. NS, Not significant. 
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Fig. 2. Actuarial survival according to completeness of resection. NS, Not significant. 
stage IV thymomas than among those with incom- 
pletely resected stage IV thymomas (5-year survivals 
64% and 34%, resPectively, confidence intervals 
36% to 91% and 0% to 72%, respectively), the 
difference was not statistically significant (p = 0.18). 
Among patients with stage III thymomas, urvivals 
were quite similar for patients with incomplete 
resections and those with biopsies (10-year survivals 
29% and 35%, respectively, confidence intervals 
11% to 47% and 5% to 65%, respectively, p = 0.85). 
Among the 260 cases of completely resected 
thymoma, 24 patients (9%) had recurrence, Disease 
recurred an average of 5.5 years after operation 
(median 3.5 years, range 2 to 16 years). Disease 
recurrence occurred an average of 8.5 years after 
operation for histologic type 1 or 2 tumors, 5 years 
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Fig. 3. Disease-free survival according to Masaoka clinical stage in patients with complete resection. 
for type 3, and 3.5 years for type 4. Recurrence was 
always in the chest (mediastinal 10, pleural or lung 
12, both 2). One patient had a concurrent liver 
metastasis. Observed recurrence rates were 3.7% 
(five patients) among patients with stage I thymo- 
mas, 7% (five patients) among patients with stage II 
thymomas, 16% (seven patients) among patients 
with completely resected stage III thymomas, and 
58% (seven patients) among patients with com- 
pletely resected stage IV thymomas (p < 0.001). 
Among the 135 patients with stage i disease, the five 
recurrences occurred in the subgroup of patients 
with stage Ib disease (with peritumoral adherence); 
there were no recurrences observed in patients with 
stage Ia thymomas. The recurrence rate was signif- 
icantly higher among patients with stage Ib disease 
than among those with stage Ia disease (p < 0.001). 
To better assess the aggressiveness of thymomas, 
we also analyzed the disease-free survival curves. 
Fig. 3 shows the disease-free survival curves for 
patients with complete resection, according to 
Masaoka clinical stage. There was a significant 
difference between disease-free survivals for pa- 
tients with completely resected stage II and stage III 
tumors (p < 0.01). No significant differences were 
found between stage I and stage II tumors, nor were 
there any differences found between completely 
resected stage III and stage IV tumors (p -- 0.80 and 
p = 0.60, respectively). 
Eighteen of the 24 patients with recurrence un- 
derwent another resection; 11 patients underwent 
complete resection and seven underwent incomplete 
resection. Survival was significantly longer among 
patients with complete resection than among those 
with incomplete resection; 10-year survivals were 
53% and 11%, respectively (log rank testp < 0.01, 
confidence intervals 19% to 87% and 0% to 32%, 
respectively). Similarly, five patients with incom- 
pletely resected stage III thymomas underwent re- 
operation after radiotherapy or chemotherapy. 
Complete resection was performed in two cases; one 
patient underwent incomplete resection and two 
underwent exploratory procedures. All these pa- 
tients died within 3 years, even in cases of Complete 
resection. 
In our experience, postoperative radiotherapy was 
advised in cases of invasive thymoma to decrease 
recurrence. Among the 114 patients with completely 
resected invasive thymomas (stage II or stage III), 
90 (80%) underwent adjuvant radiotherapy and 24 
did not receive any adjuvant treatment. Fig. 4 shows 
disease-free survival curves for the 90 patients with 
completely resected invasive thymomas who under- 
went postoperative radiotherapy and of the 24 pa- 
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tients who did not undergo postoperative radiother- 
apy. No significant differences were found. 
Fig. 5 shows the 10-year survival according to 
histological classification. No significant difference 
was found between curves for type 1 and 2 diseases. 
On the other hand, we found a borderline significant 
difference between survivals for patients with type 2 
and 3 thymomas (p = 0.07) and a highly significant 
difference between patients with type 3 and 4 dis- 
ease (p < 0.01). 
Finally, three prognostic factors were established 
in univariate analysis: completeness of resection, 
Masaoka clinical stage, and histologic lassification. 
Because histologic classification, Masaoka clinical 
stage, and completeness of resection all seemed 
linked, we performed a multivariate analysis. The 
following covariables were analyzed by multivariate 
analysis to assess their independent prognostic value 
for survival: completeness of resection, Masaoka 
clinical stage, histologic classification, association 
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with MG, and postoperative radiotherapy. By this 
method, the completeness of the resection was 
found to be the sole significant prognostic factor 
(p < 0.00001). Masaoka clinical stage should no 
longer appear as a prognostic factor because com- 
pleteness of resection and Masaoka clinical stage 
were closely linked. The same criterion applies to 
the histologic lassification. In contrast, when we 
used a four-covariable model excluding complete 
resection factor, Masaoka stage was the sole inde- 
pendent prognostic factor (p < 0.00001). Histologic 
classification never appeared as a prognostic factor 
in multivariate analysis. 
Discussion 
Prognostic factors for thymoma re difficult to 
define because these tumors are uncommon, poly- 
morphic, and slow growing. A large series and 
long-term follow-up are needed to try to define 
prognostic factors. Furthermore, 65% of the causes 
of death were independent of the tumor's progress 
(complications of an autoimmune diseases or mis- 
cellaneous diseases); survival and the disease-free 
survival curves for patients with complete resection 
therefore do not exactly reflect he aggressiveness of 
the tumor. We therefore decided to also compare 
recurrence rates. 
MG is the autoimmune disease most frequently 
associated with thymoma, and its incidence is gen- 
erally 30% or more in most reported series. 2' 4, 7 The 
unusually high proportion of patients with MG in 
our series (64% of the patients) is explained by a 
specific recruitment of thymectomy for MGI2; some 
of these patients also had a thymoma nd required a
wider surgical procedure. The prognostic value of 
MG is controversial. Maggi and associates 4 demon- 
strated a better prognosis for patients with MG, 
linked to an earlier thymoma diagnosis and less 
invasive thymoma in this group. Monden and col- 
leagues 2 found a lower recurrence rate among pa- 
tients with MG, even in cases with similar clinical 
stages. In our experience, we found an equal distri- 
bution of the clinical stages in patients with MG and 
patients with NAD. Furthermore, survivals of pa- 
tients with MG and patients with NAD were similar, 
as in most series, l'3.6, 7 
The clinical staging system described by Masaoka 
and coworkers s reflects the highly variable malig- 
nant potential of these tumors and is considered by 
most authors as the major prognostic factor. 1' 3, 4, 6 
Clinical staging must be supplemented byhistologic 
research. Wilkins and colleagues 6 pointed out the 
risk of missing a microscopic apsular invasion. 
Similarly, a tumoral invasion must be differentiated 
from a peritumoral adherence. Surprisingly, this 
classification does not take into account complete- 
ness of resection, which for most malignant tumors 
is one of the best prognostic ndicators. In our series, 
we also found the overall prognostic significance of 
Masaoka clinical stage in univariate analysis, with a 
worse prognosis in cases of invasive or metastatic 
tumor than in cases of noninvasive tumor. We 
found, however, a significant difference in survival 
between patients with completely resected stage III 
tumors and those who underwent incomplete resec- 
tion or biopsy only of stage III tumors. Similarly in 
stage IV thymomas, there was a trend toward better 
survival for patients with complete resection than 
for patients with incomplete resection. The absence 
of significance was probably a result of the lack of 
power of the test (short samples). 
As a result, completeness of resection should be 
taken into account in a clinical-pathologic classifica- 
tion, as some other authors 2's have pointed out. Our 
results demonstrated that completeness of resection 
was the major survival prognostic factor in univari- 
ate analysis, and this contention was supported by 
the multivariate analysis. This prognostic factor was 
more significant than Masaoka clinical stage. Fur- 
thermore, stage I should be divided into two sub- 
groups; in fact, even though the disease-free survival 
curves were quite similar for patients with stage Ia 
and Ib disease, the five recurrences observed in the 
stage ! group all occurred in patients with stage Ib 
thymomas. We therefore propose a modified clini- 
cal-pathologic staging system as follows: stage Ia, 
complete resection of a thymoma, macroscopically 
completely encapsulated and with no microscopic 
capsular invasion; stage Ib, complete resection of a 
thymoma, macroscopically completely encapsulated 
and with no microscopic capsular invasion, but with 
peritumoral dherences; tage IIa, complete resec- 
tion of a thymoma with macroscopic nvasion into 
surrounding fatty tissue or mediastinal p eura; stage 
IIb, microscopic invasion into capsule; stage IIIa, 
complete resection of a thymoma with macroscopic 
invasion into neighboring organ (pericardium, great 
vessels, or lung); stage IIIb, incomplete resection or 
biopsy of a thymoma with macroscopic invasion into 
neighboring organ (pericardium, great vessels, or 
lung); stage IVa, complete resection of a metastatic 
thymoma; and stage IVb, incomplete resection of a 
metastatic thymoma. 
In cases of invasive thymoma, some authors 4 have 
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found that subtotal resection allows a better prog- 
nosis than biopsy alone. As in the series of Nakahara 
and associates 5 and Cohen and coworkers, 13we 
could not confirm these results; in our series of 
patients with stage III thymomas, the prognoses 
were similar in cases of incomplete resection and 
biopsy. According to our experience, surgical resec- 
tion should be performed only in a curative attempt. 
Neoadjuvant radiotherapy or chemotherapy should 
be tested when the tumor seems marginally opera- 
ble. 13-17 Although survival was not significantly 
longer among patients with completely resected 
stage IV thymomas than among those with incom- 
plete resection or biopsy of stage IV thymomas, we 
recommend surgical resection for these patients if a 
curative resection seems possible because long-term 
survivors were observed only in the group with 
resection, and neoadjuvant radiotherapy or chemo- 
therapy could also be tested for these patients. 
Postoperative radiotherapy is usually recom- 
mended for invasive thymomas to reduce recur- 
rence.4. 6.18 Most disease recurred well after the 
surgical resection, and long-term follow-up is neces- 
sary to study this problem. Some authors 2'5 recom- 
mend postoperative radiotherapy for all thymomas; 
in our experience, no recurrences were observed 
after resection of stage Ia thymomas; we therefore 
do not recommend postoperative radiotherapy for 
this group of patients. For all other patients under- 
going resection, we continue to recommend postop- 
erative radiotherapy even though our study did not 
find any significant difference in terms of disease- 
free survival between irradiated patients and nonir- 
radiated patients. This was not a randomized study, 
and further studies are necessary to draw a definite 
conclusion. 
The value of histologic lassification of thymomas 
is still controversial; various classifications have 
been used. 9'~9'2° Some authors do not pay any 
attention to histologic type. 4' 5 By others, epithelial 
tumors were seen to have an adverse prognostic 
factor because of the high frequency of invasive 
tumors of this histologic type. 1'19 In univariate 
analysis, we also found a prognostic value of histo- 
logic classification, with a worse prognosis for pa- 
tients with differentiated pithelium-rich t ymomas 
or undifferentiated pithelium-rich t ymomas than 
for those with lymphocyte-rich or spindle or oval cell 
thymomas. The histological classification is closely 
linked to the clinico-pathological staging (Table II), 
however, and finally to the possibility of performing 
a complete resection. In multivariate analysis, the 
histologic lassification did not appear as a prognos- 
tic factor. In our experience, prognosis could be 
better evaluated by intraoperative identification and 
evaluation (extension, possibility of complete resec- 
tion) than by histologic analysis. 
In a recent article, Martinez and associates 21 
found Marino and Mtiller-Hermelinck's histologic 
classification 2° to be an independent prognostic 
factor. We did not use that histologic lassification. 
Surprisingly, these authors did not observe any 
recurrence of medullary and mixed thymomas, 
which they considered benign tumors with no risk of 
recurrence. We did not agree with their conclusions; 
our histologic type 1 is strictly comparable, as far as 
our pathologists are concerned, with the medullary 
subgroup of the Marino and Miiller-Hermelinck 
classification2°; in this subgroup of patients, we 
observed not only some invasive thymomas (seven 
stage II, seven stage III, and one stage IV among the 
67 patients) but also two long-term recurrences, 
with two deaths related to recurrence. In light of 
these facts, we could not consider this subgroup of 
thymomas to be benign tumors. Furthermore in the 
series of Martinez and associates, 21 Masaoka clinical 
stage remained the best prognostic factor, more 
significant than histologic lassification, so we think 
that our new clinical pathologic staging, including 
completeness of resection, remains the best prog- 
nostic indicator. 
Finally, in our experience only patients with stage 
Ia thymomas had no recurrence, and the prognoses 
of stage Ib and II tumors are quite similar. The 
invasion of neighboring organs (stage III) signifi- 
cantly increases the risk of recurrence even in cases 
of complete resection (stage Ilia). In stage IIIb, the 
prognosis was similar in cases with incomplete re- 
section and biopsy alone. Long-term survivors were 
observed after complete resection of metastatic 
thymomas ( tage IVa). Even though the benefits of 
adjuvant radiotherapy for invasive thymomas was 
not demonstrated, radiotherapy is recommended for
these patients until further studies have been per- 
formed. Neoadjuvant chemotherapy or radiother- 
apy should be tested in prospective trials for grossly 
invasive or metastatic thymomas, but surgical resec- 
tion should be performed whenever complete resec- 
tion seems possible. Further studies are necessary to
evaluate the value of histologic classification. A 
unified histologic and clinical-pathologic classifica- 
tion is indispensable for the sake of further studies 
(adjuvant or neoadjuvant treatment, research of 
other prognostic factors). 
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